Palisade Bio (NASDAQ:PALI) Trading Up 9% – What’s Next?

Palisade Bio, Inc. (NASDAQ:PALI)’s share price traded up 9% during trading on Friday . The company traded as high as $4.22 and last traded at $3.89. 135,870 shares traded hands during mid-day trading, a decline of 68% from the average session volume of 427,719 shares. The stock had previously closed at $3.57.

Palisade Bio Stock Performance

The company has a market capitalization of $3.64 million, a PE ratio of -0.16 and a beta of 1.34. The business has a fifty day moving average price of $3.59 and a 200 day moving average price of $4.52.

Palisade Bio (NASDAQ:PALI) last released its quarterly earnings data on Monday, August 12th. The company reported ($3.32) EPS for the quarter. Research analysts forecast that Palisade Bio, Inc. will post -13.11 earnings per share for the current fiscal year.

Palisade Bio Company Profile

Palisade Bio, Inc, a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage.